Intimation of Analyst/Investor Meet

MPS Limited

  • Event Type: Earnings Conference Call discussing unaudited financial results for Q2 and H1 FY27 ended September 30, 2026.
  • Date and Time: Held on Wednesday, November 4, 2026, at 4:30 PM IST.
  • Purpose: Discussion of quarterly results, strategic updates, and business performance across segments.
  • Management Participants:
  • Mr. Rahul Arora, Chairman and Chief Executive Officer
  • Ms. Prarthana Agarwal, Chief Financial Officer
  • Ms. Christine Miranda, Senior Vice President, Research Solutions
  • Mr. Sanjeev Talwar, Senior Vice President and Business Head, Education Solutions
  • Availability: The transcript is available on the company website at https://www.mpslimited.com/investors-overview/.
  • Compliance: The call was a scheduled earnings discussion following result announcements.

Financial Highlights Discussed:

  • H1 FY27 Revenue: INR 448.5 crores (up 17.8% YoY)
  • H1 FY27 EBITDA: INR 154 crores (up 39% YoY) at 34.3% margin
  • Q2 FY27 Margin: 34.3% (highest in recent history, second consecutive quarter above 34%)
  • Cash Position: INR 163 crores as of September 30, 2026
  • Debt: Zero debt after repaying Unbound Medicine borrowing
  • Client Diversification: 839 clients billed in quarter vs 422 a year ago; top 5 clients now 46% of revenue vs 51%
  • EBITDA Guidance: Raised floor to at least INR 310 crores for FY27 from previous INR 300 crores

Segment Performance:

  • Research Solutions: Margin reached 48.2% (up 6+ points YoY); organic growth (ex-AJE) ~22%
  • Education Solutions: 30.6% of group revenue (up from 27.2%); H1 revenue growth 36%; Unbound Medicine contributed INR 41.6 crores
  • Corporate Learning: Margin improved to 25% from ~16%; EBITDA grew 77% with 19% fewer people

Strategic Themes:

  • AI-first knowledge company focused on outcomes rather than hours
  • ISO 42001 certification for AI governance
  • Expansion into healthcare workforce learning through Unbound and Liberate integration
  • Focus on recurring revenue from subscriptions and contracted mandates
  • Rule of 50 metric (growth rate + operating profit percentage) above 50 in H1

Additional Notes Section

  • Attachments: The disclosure includes the full transcript of the earnings conference call.
  • Financial Data: Extensive financial data and performance metrics were discussed during the call.
  • Forward-looking Statements: Company provided raised EBITDA guidance and discussed upcoming mandates, US adoption cycles, and acquisition strategy.